Ondran (Ondansetron Hydrochloride Dihydrate)

Ondansetron is a selective 5‑HT3 receptor antagonist used to control nausea and vomiting in several clinical settings.

• Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed episodes.
• Radiation‑induced nausea and vomiting: helps prevent emesis during and after radiotherapy.
• Post‑operative nausea and vomiting: decreases the incidence of vomiting after surgical procedures.
• Hyperemesis gravidarum (off‑label in some regions): may be used when conventional therapy fails, under specialist supervision.

• Ondansetron blocks the serotonin 5‑HT3 receptors located on vagal afferent nerves in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By inhibiting this receptor, it prevents serotonin‑mediated stimulation of the vomiting centre, thereby reducing nausea and vomiting triggered by chemotherapy, radiation, surgery, or other emetogenic stimuli.

Side‑effect profiles reflect the drug’s pharmacology and patient variability.

Common Side Effects

• Headache: mild to moderate intensity.
• Constipation: reduced bowel motility.
• Diarrhoea: occasional loose stools.
• Fatigue: general feeling of tiredness.
• Dizziness: transient light‑headedness.

Serious or Rare Side Effects

• QT interval prolongation: may predispose to cardiac arrhythmias.
• Severe hypersensitivity: rash, itching, swelling, or anaphylaxis.
• Serotonin syndrome: rare when combined with other serotonergic agents.
• Hepatic enzyme elevation: abnormal liver function tests.
• Neuroleptic malignant‑like reactions: very uncommon but serious.

Patients should be assessed for cardiac risk and drug interactions before starting therapy.

• Cardiac monitoring: evaluate baseline ECG in patients with known QT prolongation risk.
• Concomitant serotonergic drugs: avoid or monitor for serotonin syndrome.
• Electrolyte balance: correct hypokalaemia or hypomagnesaemia before use.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment.
• Renal or hepatic impairment: dose adjustment may be required; follow prescriber guidance.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Ondansetron may alter the pharmacokinetics of several medicines and vice‑versa.

Major Interactions (Avoid)

• Apomorphine: concurrent use can cause profound hypotension and loss of consciousness.
• Certain anti‑arrhythmic agents (e.g., amiodarone, quinidine): increase risk of QT prolongation.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ondansetron plasma levels.
• CYP2D6 substrates (e.g., metoprolol, codeine): potential for altered metabolism.
• Tramadol and other serotonergic analgesics: monitor for signs of serotonin syndrome.
• Oral contraceptives: may slightly reduce efficacy; advise backup contraception.